Konruns(SH:603590) Xin Lang Cai Jing·2025-10-20 02:59Group 1 - The core point of the article highlights the recent performance of Kangchen Pharmaceutical, which saw a 5.02% increase in stock price, reaching 51.69 yuan per share, with a total market capitalization of 8.237 billion yuan [1] - Kangchen Pharmaceutical, established on September 3, 2003, and listed on August 27, 2018, focuses on innovative drug research and development, with its main revenue sources being Suling (70.77%) and Salmon Calcitonin (29.15%) [1] - The trading volume for Kangchen Pharmaceutical was 147 million yuan, with a turnover rate of 1.84% [1] Group 2 - According to data, CITIC Prudential Fund holds a significant position in Kangchen Pharmaceutical, with its CITIC Prudential Zhi Rui Mixed A Fund (003432) owning 228,000 shares, accounting for 3.05% of the fund's net value [2] - The fund has generated a floating profit of approximately 563,200 yuan today [2] - The CITIC Prudential Zhi Rui Mixed A Fund was established on October 21, 2016, with a current scale of 129 million yuan and has achieved a year-to-date return of 9.75% [2] Group 3 - The fund manager team for CITIC Prudential Zhi Rui Mixed A includes Wang Rui, Liu Hongliang, and Zhu Huiling, with Wang Rui having a tenure of 10 years and 177 days, achieving a best fund return of 253.09% during his tenure [3] - Liu Hongliang has a tenure of 1 year and 97 days, with a best fund return of 11.17% [3] - Zhu Huiling has a tenure of 202 days, with a best fund return of 10.12% [3]